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TECHNICAL NOTE
A rapid renal clearance methodology for dextran
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Dextrans are useful probes of glomerular function. As
dextrans are thought to be neither secreted nor reabsorbed by
the renal tubule [1, 2], their plasma and urine concentrations
directly reflect glomerular filtration. Indeed, renal clearance
studies using neutral dextran with different molecular weights
but uniform chemical composition allow the size selective
transport properties of the glomerulus to be directly assessed
[2—4]. Other neutral polymers such as polyvinylpyrrolidone
[5—71 and polyethylene glycol [8] have also been used.
Studies of glomerular transport using dextrans were first
attempted using fractions of limited polydispersity, treated as
single solutes [9, 10]. Difficulties were encountered, however,
since the residual polydispersity of the dextran fractions re-
sulted in a time dependence of the measured clearance as the
average molecular weight of the remaining dextran in plasma
increased [1, 11, 12]. Wallenius [1] described an alternative
approach by injecting polydisperse dextran intravenously, fol-
lowed by a molecular weight characterization of dextran in the
plasma and urine samples. This approach yielded more consist-
ent results and was especially advantageous since the entire
molecular weight range of interest could be studied in a single
experiment. The molecular weight characterization technique
of turbidimetric titration described by Wallenius [1] was of
limited resolution and proved impractical. Others subsequently
developed chromatographic techniques such as gel filtration or
gel permeation chromatography for this purpose [13—161. In
spite of these developments, renal clearance studies using
polydisperse dextran have remained tedious to perform. A
major limitation has been the time required for characterizing
the molecular weight distribution of dextran on conventional gel
permeation chromatographic systems. Moreover, maintenance
of a constant plasma concentration of polydisperse dextran at
each molecular weight, a requirement for precise renal clear-
ance determinations [17, 18], has not been technically possible
as the glomerulus ultrafilters a disproportionate fraction of the
lower molecular weight solutes in a polydisperse dextran sam-
ple.
We have described methods using high performance gel
permeation chromatography for characterizing the molecular
weight distribution of neutral dextran that can be performed
rapidly [19]. We describe below the application of this method-
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ology to renal clearance experiments in unanesthetized, con-
scious dogs and investigate the effect of changing plasma
dextran concentrations on the accuracy of dextran fractional
clearance determinations.
Methods
Seven lab mix mongrel dogs (5 female, 2 male) weighing 20 to
35 kg were each studied at least twice (usually three times) by
three different experimental protocols. Prior to each experiment
they were fasted overnight and allowed free access to water.
The animals were studied unanesthetized under minimum re-
straint.
Twenty mI/kg of 5% dextrose in water was administered over
a 20 minute period at the start of a clearance experiment to
promote diuresis. A catheter was passed into the bladder, and
plasma samples were taken for blank assays. A priming dose of
creatinine (90 mg/kg, Sigma Chemical Co.. St. Louis, Missouri,
USA), sodium p-aminohippurate or PAH (8 mg/kg, Merck
Sharp & Dohme, West Point, Pennsylvania, USA), dextran T10
(390 mg/kg, Pharmacia Fine Chemicals, Piscataway, New Jer-
sey, USA) and dextran T40 (130 mg/kg, Pharmacia) was pre-
pared in a 0.9% NaCI solution and administered as a bolus
injection. Sustaining 0.9% NaCl solutions, containing creatinine
and PAH, followed the bolus injection to replace urinary losses
of these solutes. Twenty to thirty minutes were allowed for the
equilibration of these solutions. Urine collected during this time
was discarded, and all urinary fluid loss was returned intrave-
nously as a 0.45% NaCI solution. A 20 to 30 minute clearance
interval was utilized with catheter drainage of the bladder and a
terminal air washout. Plasma samples were taken just prior to
the start and end of each of three urine collection periods.
Three different experimental protocols were performed con-
cerning the plasma concentrations of dextran. In the first case,
no additional dextran solutions were administered and the
plasma dextran concentration was allowed to fall during the
experiment. This is referred to as the bolus only protocol (B).
During the second protocol (5), dextran T10 was added to the
creatinine and PAH sustaining solutions with the amount added
approximating urinary loses of total dextran. Urinary reinfusion
(R) was performed as the third experimental protocol. Urine
was continuously collected in a small reservoir, and a pump was
used to reinfuse urine into a forelimb vein. Urine samples were
taken from the reservoir. Before reinfusion, urine was passed
through a 0.2 filter (Fischer Scientific Co., Tustin, California,
USA) to remove any bacteria that may have contaminated the
reservoir. Maintenance of a constant volume in the reservoir
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was performed by matching the flow rate of the pump to the
urine flow rate. No sustaining solution of creatinine and PAH
was used during urinary reinfusion. During this protocol, the
urinary loss of dextran is exactly balanced by reinfusion into the
blood stream making the plasma concentration at each molec-
ular weight relatively constant.
The three protocols for the administration of dextran were
selected for the following reasons. The B protocol represents
the simplest experimental strategy and has been widely used by
previous investigators. During this protocol plasma dextran
concentrations decrease rapidly during the experiment, espe-
cially those at low molecular weight that traverse the
glomerulus unimpeded. The low and falling plasma dextran
concentrations may invalidate the simple calculation of renal
clearance since this calculation dose not account for the delay
time between blood sampling and solute appearance in the urine
nor the difference between venous and arterial concentrations
[17, 18]. The S protocol seeks to correct for the rapid loss of low
molecular weight dextran by continuous replenishment of dex-
tran Tb. This replacement is, however, only an approximation
of urinary losses. The R protocol, while technically difficult and
clearly not applicable for human experimentation, provides the
best stability of all dextran plasma concentrations, as the
dextran lost in the urine is returned to the vascular space.
Artifacts of clearance that result from fluctuating plasma levels
should be minimal from experiments conducted with the R
protocol but maximum with the B protocol.
Creatinine concentrations in urine and plasma were deter-
mined using a Beckman-2 Creatinine Analyzer (Fullerton, Cal-
ifornia, USA). Concentrations of PAH were determined by the
method described by Waugh and Beall [20].
Chromatography
Chromatography was performed by using a Waters (Model
6000A) solvent delivery system with a Waters (Model U6K)
sample injector. Column effluents were monitored by using a
differential refractive index detector (Waters Model R401).
Voltage output from the detector was simultaneously monitored
by a chart recorder and an Apple 11+ microcomputer as
described previously [19]. The column buffer was 0.01 M
phosphate, pH 6.5, containing 0.15 M ammonium acetate, and
all chromatographic separations were performed at ambient
temperature. A TSK-G30005W column (60 cm x 0.75 cm, Cole
Scientific, Calabasas, California) was used and calibrated with
dextran standards of very low polydispersity [19]. The column
flow rate was set at a nominal pump setting of 1 ml/min. Sample
volumes ranged from 100 to 200 j.d forplasma and 20 to 50 tl for
urine. With this system a molecular weight characterization of
dextran can be performed in less than 45 minutes. More details
of this chromatographic system have been previously described
[19].
Sample preparation
Samples of urine and plasma were deproteinized by adding
four volumes of a saturated picric acid solution followed by
centrifugation for 15 minutes. Dextran was then recovered from
these solutions by precipitating with nine volumes of 100% cold
ethanol, lyophilizing, and reconstituting in column buffer. In-
dependent recovery experiments from plasma and urine
showed a small but significant fractionation of dextran following
treatment by picric acid. Recovery of dextran varied from
approximately 90% at low molecular weight to 100% at high
molecular weight. The recovery from plasma and urine was
quantitatively identical.
As differential refractometry is not a selective detection
system, it was important to demonstrate that the above proce-
dures resulted in signals that reflect only dextran concentration.
Figure 1 shows an example of the relative signal for blank (solid
line) and experimental (dashed line) plasma samples as a
function of the column retention volume K. The signal obtained
from the blank sample was essentially zero for retention vol-
umes less than 0.9 (dextran molecular weights greater than 1000
[19]) demonstrating that the signal is a direct measure of dextran
concentration.
Data handling and statistics
The clearance for each solute of interest (C1) was calculated
by the following equation
C = U,V/P, (I)
where U, and V are the solute concentration in urine and the
volume flow rate of urine, respectively. The value of P1 is the
arithmetic mean of the plasma concentrations that bracket the
urine collection period. Virtually identical results were obtained
when the logarithmic mean plasma concentration was alterna-
tively used. No correction was made for the delay time between
blood sampling and the arrival of the solute in the bladder for
any protocol. Since exogenous creatinine clearance has been
previously shown to be a good measure of the glomerular
filtration rate in dogs [18], dextran fractional clearance was
calculated as the ratio of dextran to creatinine clearance. The
dependence of dextran fractional clearance on molecular weight
was interpolated at 150 different molecular weights to facilitate
further calculations. The data are plotted in all figures by
connecting the fractional clearance values at these interpolated
dextran molecular weights with straight lines. The filtration
fraction (FF) was estimated by dividing the creatinine clearance
by the PAH clearance.
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Fig. 1. Relative signal from the chromatographic system as a function
of the column retention volume K for a blank (solid line) and experi-
mental (dashed line) sample from plasma. The value of K = 0.8
corresponds to a 3000 dalton dextran, K = 0.6 to a 12,000 dalton
dextran, K = 0.4 to a 29,000 dalton dextran, and K = 0.2 to a 47,000
dalton dextran [191.
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Table 1. Creatinine clearance (Ccr), PAH clearance (CPAH), filtration
fraction (FF), and urine flow rates (V) for the experimental conditions
of bolus only (B), bolus and sustain (S), and urinary reinfusion (R).
Conditions
Cr
ml/mina
CPAH
ml/min' FF
V
mi/mm
B 74.6 (15.1)C 252 (36) 0.295 (0.035) 3.88 (0.91)
S 83.1 (15.5) 273 (41) 0.303 (0.027) 4.46 (0.68)
R 66.8 (l3.l)C 232 (36)C 0.291 (0.053) 4.72 (1.38)
Estimates of the components of variance within clearance
periods of each experiment, within experiments on each dog,
within dogs, and within treatment protocols using a nested
analysis of variance [21] showed significant variance contribu-
tions at each lower level. A single mean clearance value for
each dog was therefore used in an analysis of variance with
repeated measures [221 to analyze the differences between
experimental protocols. Simultaneous multiple comparisons
were made by using a paired Student's r-test with modified
Bonferroni confidence limits [22].
Results
Measured values of creatinine clearance, PAH clearance,
FF, and urine flow rate are shown in Table I. These values and
their interanimal variability are similar to that reported by
others for unanesthetized dogs [23]. Significant differences
between the three experimental protocols were found for cre-
atinine and PAH clearance, but no differences in FF or urine
flow rates were observed. Creatinine clearance for the S proto-
col was significantly larger than for both the R and B protocols,
and PAH clearance for the S protocol was larger than for the R
protocol.
Examples of data illustrating changes in plasma dextran
concentrations during the R and B experimental protocols are
shown in Figures 2 and 3, respectively. In these figures, relative
plasma dextran concentration is plotted as a function of the
column retention volume K at various times following the
initiation of the experiment. Relative plasma dextran concen-
trations at each molecular weight were maintained relatively
constant during the R protocol but dropped substantially during
the B protocol. Figure 3 demonstrates that the decrease in
plasma dextran concentration depends on molecular weight, the
fall being greatest for the smaller solutes (larger values of K).
Plasma dextran concentration changes during the S protocol
were intermediate between the R and B protocols.
Dextran fractional clearance as a function of dextran molec-
ular weight and Stokes radius for all three experimental proto-
cols is shown in Figure 4. The values of dextran Stokes radius
R (in A) were computed by the following equation [19, 24, 25]
R = 0.305 M°47 (2)
where M is the molecular weight of dextran determined by
column calibration. The results from each experimental proto-
K
Fig. 2. Relative plasma dextran concentration plotted as a function of
the column retention volume K at various times for a typical urinary
reinfusion (R) experiment. The labels correspond to times after the
initiation of the experiment. The curves have been smoothed by hand
for clarity. The value of K = 0.8 corresponds to a 3000 dalton dextran,K = 0.6 to a 12,000 dalton dextran, K = 0.4 to a 29,000 dalton dextran,
and K = 0.2 to a 47,000 dalton dextran [19].
K
Fig. 3. Relative plasma dextran concentration plotted as a function of
the column retention volume K at various times for a typical bolus only
(B) experiment. The labels correspond to times after the initiation of the
experiment. The curves have been smoothed by hand for clarity. The
value of K = 0.8 corresponds to a 3000 dalton dextran, K = 0.6 to a
12,000 dalton dextran, K = 0.4 to a 29,000 dalton dextran, and K = 0.2
to a 47,000 dalton dextran [19].
col showed a dependence of dextran fractional clearance on
molecular weight comparable to that reported by others [1, 2,
II]. As the molecular weight decreases, the fractional clearance
increases until approximately 8000 daltons (R = 21 A) upon
which further decreases in molecular weight lead to a decrease
in the fractional clearance. The dextran fractional clearance for
the B protocol was significantly lower than for the R and S
protocols at only scattered dextran molecular weights between
3000 and 5000 daltons when only (-tests were performed [26].
When the more powerful statistical test of analysis of variance
was employed, however, significant differences in dextran
fractional clearance were found between the experimental
protocols from 3000 to 18,900 daltons. Subsequent (-tests with
modified Bonferroni confidence limits failed to identify which
individual protocols were different.
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Discussion
The present study describes a new method for the molecular
weight characterization of dextran for use in renal clearance
experiments. The chromatographic equipment and columns
were previously studied [19]. Since a nonspecific refractive
index detector is used with the chromatographic system, the
successful application of this approach in renal clearance stud-
ies requires that dextran be first isolated chemically from urine
and plasma. With the technique described, dextran is almost
completely recovered and the output signal from the chromato-
graphic system is dependent only on dextran concentration in
both the plasma and urine samples. In agreement with these
observations, Wallenius [1] previously reported complete dex-
tran recovery using similar chemical isolation techniques. Fig-
ure 5 compares dextran fractional clearance obtained by the S
protocol with results from two previous studies using dextran in
dogs [1, 27]. The present results are in reasonable agreement
considering the differences in methodology used. The primary
advantage of the present method is the speed of analysis with
improved chromatographic resolution [28, 29].
The present study also examines the effect of changing
plasma dextran concentration on its measured fractional clear-
ance. For this purpose, it would be ideal if the different
experimental protocols did not substantially affect glomerular
function. Table 1 shows that differences in renal plasma flow
rate and glomerular filtration rate occur during each experimen-
____
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Fig. 5. Dextran fractional clearance plotted as a funciton of dextran
molecular weight and Stokes radius for the S protocol compared with
previously published data. Previous data is shown by either open [1] or
closed [271 circles.
tat protocol and that some were statistically significant. As the
present study was not designed to investigate these differences,
we cannot provide a unique explanation for these results. We
note only that during the R protocol, some hemolysis of red
blood cells was observed that may have resulted in decreased
creatinine and PAH clearances. The presence of free hemoglo-
bin in plasma has been shown previously [30] to result in a
simultaneous decrease in renal plasma flow rate and glomerular
filtration rate similar to that described here. This effect of free
hemoglobin may dominate the profound natriuresis that has
been observed during urinary reinfusion in rats [31].
The differences in renal plasma flow rate and glomerular
filtration rate between protocols somewhat complicate the
interpretation of fractional clearance data since dextran frac-
tional clearance has been shown previously to depend on
glomerular hemodynamic conditions [2—4]. In the absence of
changes in glomerular membrane properties, such as membrane
area or permeability (that is, constant Kf), the fractional clear-
ance of macromolecules varies inversely with SNGFR [4] or
equivalently glomerular filtration rate. It is, however, important
to note that large changes in hemodynamic parameters are
necessary to alter dextran fractional clearance. For example,
Chang and co-workers [2] determined a maximum decrease in
dextran fractional clearance of 0.14 following a twofold increase
in glomerular filtration rate and a threefold increase in renal
plasma flow rate. The observed differences between protocols
in renal plasma flow rate and glomerular filtration rate of 20 to
25% are, therefore, unlikely to have substantially affected
dextran fractional clearances. While we cannot rule out the
possibility that changes in glomerular hemodynamics altered
858 Leypoldt et al
1.2
1.0
U
C C
0.8
0.6 .2t U
cO.4
0.2
0.0
3 50
Dextran molecular weight x iO
I I I I
13 15 20 30 40 50
Dextran stokes radius, A
Fig. 4. Dextran fractional clearance plotted as a function of dextran
molecular weight and Stoke radius for the bolus only (B), bolus and
sustain (S), and urinary reinfusion (R) experimental protocols. The
vertical bars shown at selected data points illustrate the standard error
of the mean. The horizontal bars denote regions of significant difference
between the three experimental protocols as determined by analysis of
variance with repeated measures. A single asterisk denotes P < 0.05
and a double asterisk P < 0.01.
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dextran fractional clearance, we note that these changes in
hemodynamic conditions could only explain the differences
between the R and S protocols.
The significant difference in dextran fractional clearance
between the experimental protocols over the molecular weight
range from 3000 to 18,900 is consistent with previous work on
renal clearance methodologies [17, 18] and emphasizes the
importance of maintaining a constant plasma concentration in
studies of low molecular weight dextran. The errors incurred
during the bolus only protocol may have resulted from either
neglecting the delay time or sampling venous instead of arterial
blood [32]. The latter phenomena results in errors that are
largest for solutes that are rapidly cleared by the kidney and
have large diffusional barriers to capillary—tissue transport. The
magnitude of the difference in dextran fracional clearance
between the S and B protocols for dextran with a Stokes radius
of 15 A is 8%. This value is in agreement with data reported for
inulin by others (7%) [32]. These observations suggest that
errors in dextran fractional clearance caused by rapidly chang-
ing plasma concentrations are small yet identifiable and that
clearance studies using low molecular weight dextran should be
performed with sustaining doses. It is important to note,
however, that dextran fractional clearance is independent of
changing plasma concentrations for dextran greater than 18,900
daltons, the molecular weight region of most interest in studies
of glomerular barrier function.
Several previous studies [1, 2] have reported experimental
data supporting the absence of significant secretion or reabsorp-
tion of dextran by the renal tubules. The present results,
however, suggest that dextran of very low molecular weight
(less than 5000 daltons) may be significantly reabsorbed. The
smaller dextran fractional clearance observed for very low
molecular weight dextran (Fig. 4) was independent of the
experimental protocol employed and was present in every
animal studied. It is noteworthy that all previous studies
supporting the absence of tubular reabsorption or secretion of
dextran were limited to solutes with Stokes radii greater than 18
A [1, 2].
The decrease in dextran fractional clearance at very low
molecular weight does not appear to result from the present
methodology for three reasons. The recoveries of dextran from
plasma and urine are quantitatively identical. The present
results are in reasonable agreement with previous studies using
dextran over the molecular weight range from 8000 to 50,000
daltons (18 to 50 A) in dogs (Fig. 5) and other species [2, 11].
Moreover, we have shown previously [33] that this methodol-
ogy yields results for in vitro experiments on hemofiltration
membranes from human plasma solutions that are similar to
those reported by others using different techniques.
In summary, we have described the application of a new
method for characterizing the molecular weight distribution of
dextran that permits more rapid processing of samples than
conventional techniques. Using these methods, dextran frac-
tional clearance for molecular weights between 8000 and 50,000
is similar to that reported previously. It is recommended that
the determination of dextran fractional clearance at low molec-
ular weight should be performed by using a sustaining dosage to
prevent rapidly changing plasma dextran concentrations.
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